key: cord-0715878-pvz582cb
authors: Sparks, Amy E.T.; Kresowik, Jessica D.
title: Infection precautions for SARS-CoV-2 in assisted reproduction centers – dodging an invisible bullet
date: 2021-01-14
journal: Fertil Steril
DOI: 10.1016/j.fertnstert.2021.01.016
sha: 76ec30bdf4bf9dc9915593749a3f4738517d267d
doc_id: 715878
cord_uid: pvz582cb

The COVID-19 pandemic has forced many changes to how we interact in society, requiring that we protect ourselves and others from an invisible, airborne enemy called the SARS-CoV-2 virus. Until a vaccine is discovered and reaches high levels of distribution, everyone must continue to be diligent to limit viral spread. The practice of assisted reproduction during this pandemic presents unique challenges in addition to the risks that have been identified for general clinical care. The established good tissue practices employed in laboratories are not designed to protect gametes and embryos from an airborne virus, particularly one that may be shed by an asymptomatic staff member. Armed with theoretical risks, but lacking direct evidence, assisted reproduction teams must examine every aspect of their practice, identify areas at risk for exposure to the SARS-Cov-2 virus and develop a mitigation plan. Several professional fertility societies have created guidelines for best practices in patient care during the COVID-19 pandemic. As we learn more about SARS-CoV-2 updates have been issued to help adapt infection control and prevention protocols. This review discusses what is currently known about SARS-CoV-2 infection risks in assisted reproductive centers and recommends implementation of specific mitigation strategies.

Severe acute respiratory coronavirus 2 (SARS-CoV-2) is a highly transmissible virus that causes an acute respiratory disease called the 'coronavirus disease 2019' . It accomplishes this feat primarily through respiratory droplets (> 5 um diameter) and possibly aerosols (<5 um diameter) released when a person exhales, coughs, sings or talks. The virus is acquired through droplet inhalation/entry into the eyes, direct contact with another person, or by touching a surface that harbors the virus-loaded droplet.

After direct or indirect contact, the virus is introduced to the host after they touch their eyes, nose or mouth (1) (2) (3) (4) . Much has been learned about this novel virus during the pandemic including its variable incubation period, ranging from 2-14 days, and ability to spread from non-symptomatic or presymptomatic individuals (5) (6) (7) (8) . The variable and lengthy incubation period of SARS-CoV-2, the potential for asymptomatic spread, the lack of an accessible, accurate, and rapid diagnostic tool make avoiding this contagion a significant challenge (9) .

Early during the COVID-19 pandemic, assisted reproduction was one of many medical services that paused patient care to protect patients and healthcare workers, conserve PPE and human resources to reduce the strain on the health care system (10, 11) . As centers prepared to resume patient care it was quickly recognized that their pre-pandemic infection control procedures that focused on universal precautions were an insufficient defense against a highly contagious, aerosol-mediated respiratory virus that can be shed and transmitted by asymptomatic or pre-symptomatic individuals (12) (13) (14) . In response, professional fertility societies and working groups across the globe promptly formed taskforces to develop strategies and identify best practices for assisted reproduction programs to provide safe and effective patient care while mitigating the risk of COVID-19 infection. Several updates to these recommendations have been made as we develop a better understanding of how to protect, patients, J o u r n a l P r e -p r o o f healthcare workers and realize the risks of SARS-CoV-2 exposure to gametes, embryos and reproductive tissues.

The aim of this review is to conduct a systematic review of SARS-CoV-2 infection risks and practice guidelines for infection control in assisted reproductive technology (ART) centers providing patient care during the COVID-19 pandemic.

We performed a review to identify studies of SARS-CoV-2 infection risk in patients seeking infertility care along with professional fertility societies' guidelines and individual recommendations for mitigation of SARS CoV-2 transmission while providing assisted reproductive care. The electronic databases OVID Medline and PubMed were searched for articles published from December 1, 2019 through October 20, 2020. We performed the search using the MeSH terms "assisted reproduction" OR "infertility" AND "COVID-19" and restricted the publications to English language and human subjects. An additional manual search of results from a Google Scholar search based upon the same MeSH terms was performed. Professional fertility society guidelines that were not published as manuscripts were accessed from their web sites.

The initial search of OVID Medline and PubMed databases identified 271 publications relevant to assisted reproduction or infertility and COVID-19. An overview of the study inclusion is presented in Figure 1 . Studies of risks assessment for SARS-CoV-2 infection in ART centers, recommendations from regional, national and international fertility working groups and professional fertility societies for infection control and studies of SARS-CoV-2 infection in gametes, embryos and gonads. Investigations on J o u r n a l P r e -p r o o f the impact of COVID-19 on reproductive health and pregnancy, the psychological effects of the delay of infertility care due to the pandemic, and letters to the editor commenting on national or international responses to the SARS-CoV-2 infection prevention guidelines, were excluded.

The articles and dates of acceptance describing SARS-CoV-2 infection risks specific to ART clinics and laboratories are in Table 1 . Guidelines accessed from professional fertility societies' websites are listed in Table 2 . Readers must be mindful of the dates of manuscript acceptance or guideline publications as they reflect the knowledge of SARS-CoV-2 threats to the ART centers at that time.

Centers must assume that everyone is potentially infectious and add additional infection prevention and control practices to their standard policies and procedures thereby reducing the risk of SARs-CoV-2 transmission (9, 12) . In order to achieve this goal, the program needs to identify all levels of risk associated with continuing to deliver patient care. A failure modes and effect analysis (FEMA) conducted by a multidisciplinary ART team at the GENERA centers in Italy, identified the following four areas of potential risk for bi-directional infection in the ART clinic: patient-staff, staff-staff, staff-cell and cell-cell (18) . Their assessment identified risks associated with all phases of ART laboratory procedures, failures that would result in SARS-CoV-2 exposure and corrective measures to avoid such failures.

Professional fertility societies guidelines advise programs to conduct their own risk assessments for providing patient care during the pandemic as the risks will vary based upon staffing, physical space, PPE supplies, local infection rates and other factors unique to their program (23, 24, 26) . The risk categories identified by the GENERA team were used to structure the findings of our review of infection precautions for ART centers.

J o u r n a l P r e -p r o o f

The following strategies were identified by all professional fertility societies to reduce the risk of patient to staff and staff to patient transmission in the ART center.

Patients and staff must be educated and required to follow best practices for infection control to reduce the risk of exposure to SARS-CoV-2 at home, in the community and at the workplace ( Table 3 ). All fertility societies recommend including these practices in a written document for staff and patients with regular reminders and repeated confirmation of compliance (23) (24) (25) (26) (27) (28) .

A COVID-19 symptom assessment should be conducted for all staff and patients requiring an in person visit or any other individuals who must gain entry to the ART center. The components of the questionbased assessments were consistent across all fertility society guidelines with some recommending temperature checks and one guideline recommending pulse oximeter checks for everyone entering the center (Table 4 ). Patient screening may be conducted over the phone in advance of their visit or through a mobile application. A recent review of screening recommendations from four of the national/international reproductive medicine societies suggested that adoption of a COVID-19 selfassessment application could relieve staff of the additional phone call burden and assure triage questions align with currently identified symptoms and geographical viral prevalence (29) .

Recommendations for patient testing as an adjuvant to the triage with or without a positive screen varied with professional fertility societies often deferring to institutional or other authoritative sources to guide testing and quarantine measures.

Limiting Patient Visits and Time in the ART Center J o u r n a l P r e -p r o o f When possible, clinics should utilize telehealth (either phone or secure video) in lieu of in-person clinic visits. When in-person visits cannot be avoided, the number of individuals in the facility should be limited. To achieve this, clinic and procedure schedules should be adjusted to allow adequate time to disinfect patient care space between appointments. Clinics should minimize the number of visits required for monitoring ovarian stimulation. Access to the clinic should be restricted to the patient having a clinic visit or procedure. If the facility permits visitors, they must follow universal source control procedures.

Preventative measures for SARS-CoV-2 transmission from asymptomatic and pre-symptomatic individuals requires everyone in the ART center wear facemasks, facilitate physical distancing, use frequent hand hygiene by washing hands with soap and water or alcohol based hand-sanitizer with 60-95% alcohol, and disinfect patient care areas between each patient. Additional diligent, daily disinfection of the entire ART center is required.

A description of recommended PPE for healthcare providers and patients from the ASRM COVID-19 recommendations is in Table 5 . Every fertility professional society emphasized the need for centers to assure that their PPE inventory meet these requirements to protect their patients and staff. Staff with potential exposures to aerosols must be fitted for N95 masks that provide protection from 95% of >0.3 um aerosols.

In order to facilitate physical distancing, marks of a 6-foot distance should be established in the registration area and seating adjusted in the waiting room, consultation rooms and communal staff areas to maintain the prescribed distance. If waiting room space is limited, patients may be required to J o u r n a l P r e -p r o o f wait outside the center. Traffic patterns should be created throughout the center to allow individuals to avoid situations that would require them to be closer than 6 feet. Physical barriers should be installed in previously open staffing areas and reception areas (25, 26) .

Every building occupant has a role in disinfection. The rules of hand hygiene were outlined in detail by the Canadian Fertility and Andrology Society and SAMeR Task Force in Argentina (22, 25) . In addition to standard practices, centers are advised to increase the availability of alcoholbased hand gel stations including one at the center's entrance for everyone to use when entering the building (22) .

The SARS-CoV-2 has been shown to remain viable on surfaces for days so every surface touched by occupants of the ART center should be considered at risk for contamination (30) . The single-stranded RNA is enveloped by a glycoprotein membrane, making it susceptible to disinfectants including sodium hypochlorite (0.1%), bleach (0.1%-1%), ethanol (62-71%), hydrogen peroxide and quaternary ammonium compounds (16, 31) . Quaternary ammounium compounds are recommended for disinfection in in vitro fertilization (IVF) laboratories as their use does not generate volatile organic compounds that may be harmful to embryos and gametes in culture (15, 21, 22, 32) .

The SAMeR Task Force (22) provided an excellent, detailed description of cleaning tasks by area, frequency, disinfection products and methods. In addition to disinfection, they recommend removing extra surfaces such as decorative items and reading materials from the waiting room to reduce the disinfection burden. Disinfection between users is especially important for shared equipment such as touch pads, pens and keyboards that had previously had infrequent and non-routine cleaning (17, 27) .

The air born properties of the SARS-CoV-2 and potential for it to be circulated by the center's heating, ventilation and air conditioning (HVAC) system should be factored into the procedure and clinic visit schedule. Hickman et al. proposed that two complete air exchanges be required between room use while another group endorsed assuring sufficient air exchanges between room utilization without prescribing the specific number (15, 18) .

There are no specific requirements for air quality in IVF procedure areas or IVF laboratories. Programs that use a controlled HVAC system should avoid having positive pressure in a procedure area as the airflow could produce an increase in the viral spread from patients shedding the SARS-CoV-2 virus.

Ideally, the ART laboratory should be positive to patient procedure areas (17, 33) . High-efficiency particulate air filters remove particulates measuring >0.3 um from circulation, but do not provide protection from smaller, aerosolized viruses. However, air handlers equipped with activated carbon filters intended to absorb volatile organic compounds have been reported to absorb viral particles (21, 34) .

In addition to the measures discussed to prevent patient to staff SARS-CoV-2 transmission, recommendations to prevent staff to staff transmission include staff self-monitoring of symptoms before arrival to work. All professional fertility societies advised that practices must have policies in place for quarantine and testing requirements for employees reporting a high-risk exposure or symptoms.

Staffing schedules J o u r n a l P r e -p r o o f All professional societies endorsed the creation of non-overlapping shifts with split teams of staff to further reduce the risk of exposure should a member of the team become infected. The teams must be given enough time for disinfection of the entire workspace between shifts. While ideal in concept, some ART programs in the USA have come to realize that this may not be possible for centers with a small number of staff or those returning to pre-pandemic patient volumes (27). Regardless of the program's ability to split staff into teams and strict adherence to universal control procedures, there is a risk that multiple employees could simultaneously experience either high-risk exposures outside of work or become infected with SARS-CoV-2. In recognition of this possibility, programs are encouraged to make emergency arrangements to transfer patient care to another clinic and/or establish reciprocal staffing support to assure patient care is not interrupted (24 -28) .

Procedure suite and laboratory precautions Laboratory staff should rely upon hand washing and avoid using alcohol-based hand gel for hand hygiene before entering the ART laboratory as alcohol is a source of volatile organic compounds that may adversely affect human gametes and embryos. Gloves should be worn when handling and/or wiping down packages, especially when the packages have been recently handled by delivery staff and require immediate opening (17, 27) . Staff should pay extra attention to disinfection of items brought into and out of the laboratory and before initial refrigeration of consumable items such as culture media (16, 17, 22, 28) .

The laboratory staff must be diligent about frequent disinfection of shared pipettors, timers, pens, microscopes (including eye pieces) and other surfaces in the lab that are touched (18, 22) . The use of UV irradiation in combination with use of chemical disinfectant in biological safety cabinets or laminar flow hoods to kill all viruses (16, 21, 22, 28) .

When the professional fertility society guidelines for resumption of patient care were written, little was known regarding the risks SARS-CoV-2 posed to gametes and embryos. The knowledge that has been gained since is associated with primarily theoretical risks. There are currently no reports of describing SARS-CoV-2 infecting sperm, oocytes or embryos, but investigations of the potential for SARS-CoV-2 to bind and fuse with their cell membranes have been published (35, 37, 38) . The SARS-CoV-2 enters cells by binding its spike glycoprotein to the host cell's zinc metallopeptidase angiotensin-converting enzyme 2 (ACE2) receptor and relying on the cellular transmembrane protease serine (TMPRSS) to cleave the viral spike glycoprotein, allowing the viral and host cell membranes to fuse (39, 40) . Inhibition of TMPRSS2 can block SARS-CoV-2 entry so cells with the ACE2 receptor alone may not make a cell vulnerable to SARS-CoV-2 (39).

Another potential host receptor for viral entry called CD147 or Basigin (BSG) was recently identified (41) . Both ACE2 and BSG receptors are present in the testis, uterus, ovaries and placenta with the testis having the second highest number of ACE2 receptors after the lungs (19, 37, 38) . Low proteomic expression for ACE2 had been reported for nonhuman primate primary oocytes but was undetectable by 

Not all ART laboratories required staff to wear face masks and gloves when working in the lab prior to the COVID-19 pandemic. These PPE were typically reserved for patient procedures and handling samples for genetic analysis (15) . Likewise, eye protection was traditionally only used when working with cryopreserved specimens. The topic of PPE use in the ART laboratory was discussed during an international COVID-19 symposium for laboratory managers (15) . Everyone agreed they would continue to use gloves and masks during procedures and most, but not all, planned to extend their use for all time spent in the laboratory. A similar conclusion was drawn by the laboratory societies in the USA recommending that laboratories not requiring extended glove use be cognizant of the need for frequent hand washing and perform more surface cleaning (27). Hickman et al. (15) noted that the laboratory would need to select permissive eye protection given the impracticality of face shields during microscopy. Adoption of additional disinfection procedures and proper use of gloves, surgical masks and eye protection for handling cryo-storage devices also were identified as means to reduce staff to cell transmission of SARS-CoV-2 (15, 22) .

There were no recommendations for additional steps to mitigate cell-cell transmission beyond guidelines that have been previously established for reducing the risk of cross-contamination for cases of sexually transmitted diseases (13, 21, 43) . Pomeroy and Schiewe (20) reviewed existing good tissue practices as related to IVF, embryo biopsy and vitrification during the COVID-19 pandemic. They noted that even though a "soup of microorganisms" exists in our laboratories, there have been no reports of cross-contamination or vertical transmission of a disease from gametes or embryos to a patient. While the lack of reports of cross contamination or vertical transmissions are encouraging, it is important to recognize that patient testing for sexually transmitted diseases prior to bringing their gametes into an IVF laboratory or liquid nitrogen storage tank is one of the defenses routinely employed by ART clinics.

Recommendations for incorporation of COVID-19 testing into the patient evaluation prior to procedures vary greatly, deferring to local or national guidelines, institutional policies and availability of tests (23) (24) (25) . Most guidelines discuss testing patients during their treatment, but a positive test did not consistently warrant cycle cancellation for oocyte retrieval, nor should a clinic assume a negative test received as late as the day before a procedure guarantee that the patient will be negative when they arrive for their procedure (27, 29).

One of the more aggressive testing plans was described in the guidelines from the India fertility societies and based upon regional policies (28) . They recommended patients be instructed to socially isolate for two weeks prior to stimulation, requiring male and female partners to be tested by RT-PCR as early as treatment day 2 and as late as 48 hours prior to intrauterine insemination or in vitro fertilization. A positive COVID test for the patient or partner resulted cycle cancellation . Strict testing requirements were also recommended for andrology services in Brazil, proposing SARS-CoV-2 testing by RT-PCR or blood antibody be performed on all males before any andrology services were provided (19) . They J o u r n a l P r e -p r o o f recommended that only PCR negative patients or those acquiring IgG antibodies should be treated or have sperm cryopreserved. It is important to note that this recommendation was made at a time when

Brazil was the epicenter of the SARS-CoV-2 pandemic, illustrating an example of adjustment to the patient triage plan based upon regional infection rates.

Regardless of the ART center's patient testing policies and lack of evidence that SARS-CoV-2 is in follicular fluid, embryologists are advised to remove cumulative complexes from follicular fluid as quickly as possible. This practice follows guidelines for reducing viral load by incorporating additional washing of the cumulus complexes and of the oocytes after cumulus digestion to dilute any contaminants (13, 16-18, 20-22, 24, 27) .

Laboratories may want to double wrap and/or clean the outside of the specimen containers prior to handling semen (21, 22) . Sperm isolation methods aimed to process and minimize viral contaminants in semen of positive-tested patient should be used in all patients and the centrifugation of raw semen should be avoided (20) . In order to achieve this goal, use of a density gradient was commonly prescribed (16, 21, 22) .

Other considerations for specimen handling included the use of filtered micropipette tips and additional rinsing steps before cryopreservation or embryo transfer (16, (20) (21) (22) . There is no evidence of SARS-CoV-2 infection from waste, however several groups recommended additional steps be taken to assure that containers housing seminal plasma, supernatants from semen centrifugation and follicular fluid are well sealed before disposal (17, 21, 24) . Cryopreservation J o u r n a l P r e -p r o o f Like many viruses, there is a good chance, but no direct evidence that SARS-CoV-2 will survive the low temperatures of liquid nitrogen and liquid nitrogen vapors. Despite the number of pathogens that linger in liquid nitrogen storage tanks, there has been no direct evidence of disease transmission by a transferred cryopreserved embryo in humans or animals (44) . Cobo et al. (45) were unable to detect viral RNA or DNA sequences in spent culture media after embryo culture, and in liquid nitrogen used for oocyte or embryo vitrification in patients seropositive for HIV, HCV, and HBV undergoing IVF cycles. The lack of evidence to support a very strong theoretical risk may be due to the relatively low viral load associated with the washed oocyte or embryo, especially when the viral load is further reduced by loading them onto the vitrification device in a very small volume. While these previous studies are reassuring, the pathogens studied were not spread by aerosols. The risk assessment by Maggiulli et al (18) , ranked cryo-storage as the most sensitive step of the entire IVF process during the COVID-19

pandemic. They determined that there was high risk area for failure should staff fail to use proper PPE when entering the storage tank and unknowingly shed SARS-CoV-2 into the liquid nitrogen.

Several groups recommended using a closed, high security system for semen cryopreservation (15) (16) (17) (19) (20) (21) (22) . This also was the recommendation of some, but not all groups for vitrification of oocytes and embryos as many ART laboratories are accustomed to using an open system for oocyte and embryo vitrification. Laboratory managers that participated in the International COVID symposium agreed that use of a closed system merited consideration, but at the time of the symposium, did not reach a unanimous opinion due to reported increase success rates associated with open systems (15) . Use of a closed system for vitrification and avoiding a breach of the zona pellucida prior to vitrification were proposed as methods to mitigate the risk of SARS-CoV-2 infection of embryos and oocytes, with some restrictions to SARS-CoV-2 positive patients (20, 21, 24, 28) . In absence of specific directives for changes to good tissue practices by regulatory agencies, specifically cryo-storage, during the COVID-19 pandemic, the ART community is left to conduct their own cost/risk analysis when considering adaptations in their cryopreservation program (46) . This is difficult when much of the risk is the theoretical. Pomeroy and Schiewe (20) summed the situation up nicely when they said, "We must think hard about the worst-case scenario and then ask if we have the right to gamble with our patient's future based on protocols for the best-case scenario?" Cryopreservation of gametes and embryos is a critical service in assisted reproduction. We need to ensure we are delivering the best care for our patients' future family building.

The COVID-19 pandemic has presented ART centers a unique opportunity to assess every element of their practice. Many of the actions recommended for defense against SARS-CoV-2 infection in the ART center were made in absence of scientific evidence, but rather a general understanding of disease transmission and theoretical risks. The use of additional PPE, increased disinfection, limiting person to person contacts, and extended use of gloves and face coverings in the lab are logical ways to increase safety in our laboratories. Patient and partner testing if available may increase the awareness of laboratory personnel and could impact cryopreservation protocols. As the pandemic continues, our understanding of its behavior and knowledge as to how to best contain its spread will grow and result in additional forthcoming recommendations. In the meantime, ART centers must be attentive to the need to maintain staff, supplies and clean space to deliver safe and effective care while dodging the persistent and invisible SARS-CoV-2 virus. J o u r n a l P r e -p r o o f 

Transmission of SART-CoV-2: implications for infection prevention precautions

Evidence of airborne transmission of the severe acute respiratory syndrome virus

Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination

Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1

Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility

Early transmission dynamics in Wuhan, China of novel coronavirus -infected pneumonia

A familiar cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

Five-minute point-of-care testing for SARS-CoV-2: not there yet

American Society for Reproductive Medicine. Patient Management and clinical recommendations during the Coronavirus (COVID-19) pandemic

Assisted reproduction and COVID-19. A statement from ESHRE for phase 1 -Guidance on fertility services during pandemic

Infection control in healthcare personnel: infrastructure and routine practices for occupational infection prevention and control services

Recommendations for reducing the risk of viral transmission during fertility treatment with the use of autologous gametes: a committee opinion

Assisted reproduction and COVID-19: a joint statement of ASRM, ESHRE and IFFS

Managing the IVF laboratory during a pandemic: international perspectives from laboratory managers

Croatian Society of Clinical Embryologist -guidelines on the epidemiological framework for the implementation of medically assisted reproduction (MAR) procedures during the COVID-19 pandemic regarding the safety of patients and medical health workers

COVID-19: New adaptation for IVF laboratory protocols

Assessment and management of the risk of SARS-CoV-2 infection in an IVF laboratory

Concise practice recommendations for the provision of andrological services and assisted reproductive technology for male infertility patients during the SARS-CoV-2 in Brazil

Cryopreservation and IVF in the time of Covid-19: what is the best good tissue practice (GTP)?

IVF Laboratory COVID-19 pandemic response plan: a roadmap. Middle East

COVID-19 risk assessment and safety management operational guidelines for IVF center reopening

American Society for Reproductive Medicine. Patient Management and clinical recommendations during the Coronavirus (COVID-19) pandemic

ESHRE guidance on recommencing ART Treatments. ESHRE COVID-19 Working Group

Fertility care during the COVID-19 pandemic: guiding principles to assist Canadian ART clinics to resume services and care

Laboratory guidance for commencing or continuing ART operations during the ongoing COVID-19 pandemic. Guidance from the SART, SRBT and CRB

Joint IFS-ISAR-ACE Recommendations on resuming/opening up ART services

COVID-19 screening during fertility treatment: how do guidelines compare against each other?

Environmental and decontamination issues for human coronaviruses and their potential surrogates

Cleaning and disinfection of environmental surfaces in the context of COVID-19

Potential risks of SARS-CoV-2 infection on reproductive health

Cairo consensus on the IVF laboratory environment and air quality: report of an expert meeting

Analysis on preparation, application, and recycling of activated carbon to aid in COVID-19 protection

No evidence of severe acute respiratory syndromecoronavirus 2 in semen of males recovering from coronavirus disease 2019

Clinical characteristics and results of semen tests among men with coronavirus disease

Coronovirus disease-19 and fertility: viral host entry protein expression in male and female reproductive tissues

SARS-CoV-2 host receptors ACE2 and CD147 (BSG) are present on human oocytes and blastocysts

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Structural basis for the recognition of SARSCoV-2 by full-length human ACE2

CD147 as a target for COVID-19 treatment: suggested effects of azithromycin and stem cell engagement

SARS-CoV-2 entry factors: ACE2 and TMPRSS2 are expressed in peri-implantation embryos and the maternal-fetal interface

Semen decontamination for the elimination of seminal HIV-1

A review of the risk of contamination of semen and embryos during cryopreservation and measures to limit cross-contamination during banking to prevent disease transmission in ET practices

Viral screening of spent culture media and liquid nitrogen samples of oocytes and embryos from hepatitis B, hepatitis C, and human immunodeficiency virus chronically infected women undergoing in vitro fertilization cycles

Cryopreservation in reproductive medicine during the COVID-19 pandemic: rethinking policies and European safety regulations

Eye protection devices, such as goggles, glasses with solid side shields or face shields are advised

html) or if required by policy in hospital-based centers Reprinted with permission from: American Society for Reproductive Medicine (ASRM) Patient management and clinical recommendations during the coronavirus (COVDI-19) Pandemic. Update #7

ASRM: Copyrighted 2020 by the American Society for Reproductive Medicine